Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion type Assertion NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_head.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion description "[Associations of epidermal growth factor (EGF) 61A>G, EGF receptor (EGFR) CA(14-22), cyclin D1 (CCND1) 932G>A, fragment-C gamma receptor (FCGR) 2A 535A>G and FCGR3A 818A>C polymorphisms with progression-free survival (PFS) and cetuximab-related skin toxicity were studied.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_provenance.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion evidence source_evidence_literature NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_provenance.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion SIO_000772 20418097 NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_provenance.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion wasDerivedFrom befree-20140225 NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_provenance.
- NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_assertion wasGeneratedBy ECO_0000203 NP801014.RAXpt7nj1XD4_mr5oGx0e7gQyMv332a6XuCoXTg_jV6H8130_provenance.